Prof Linda Mileshkin
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
547 Scholarly works
20 Projects
HIGHLIGHTS
2026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62026
Journal article
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.
DOI: 10.1200/JCO-25-029742020
Research Grant
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2020
Research Grant
ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
2015
Journal article
Whole-genome characterization of chemoresistant ovarian cancer
DOI: 10.1038/nature144102013
Journal article
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
DOI: 10.1002/path.4251
RECENT SCHOLARLY WORKS
2026
Journal article
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting
DOI: 10.1016/j.ijgc.2026.1048272026
Journal article
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma
DOI: 10.1016/j.ejca.2026.1168852026
Journal article
Assessing Foundation Models for Computational Pathology in Endometrial Cancer.
DOI: 10.1016/j.modpat.2026.1010702026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Conference Proceedings
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
DOI: 10.1200/jco.2026.44.16_suppl.55152026
Journal article
Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).
DOI: 10.1200/jco.2026.44.16_suppl.41062026
Journal article
Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
DOI: 10.1016/j.modpat.2026.101000